What are the dosing guidelines, indications, contraindications, and monitoring recommendations for bupropion in adults?

Bupropion: Clinical Guidelines for Adults

Primary Indications

Bupropion is FDA-approved for major depressive disorder (MDD) and smoking cessation, with established efficacy as a norepinephrine-dopamine reuptake inhibitor that offers unique advantages over serotonergic antidepressants. 1

Approved Uses:

• Major Depressive Disorder (MDD) - Comparable efficacy to SSRIs with superior tolerability profile regarding sexual dysfunction and weight gain 2
• Smoking Cessation - Effective as monotherapy or combined with nicotine replacement therapy 3
• Seasonal Affective Disorder (SAD) 1
• Off-label: Weight management (as naltrexone-bupropion combination) 3

---

Dosing Guidelines

For Major Depressive Disorder:

Standard Dosing Algorithm:

• Days 1-3: 150 mg orally once daily in the morning 1
• Day 4 onwards: 150 mg orally twice daily (if tolerated) 1
• Maximum dose: 300 mg per day for sustained-release formulations 3
• Extended-release (XL) formulation: Can be given once daily up to 450 mg for immediate-release or 400 mg for sustained-release 4, 5

Key Dosing Principles:

• Gradual titration is mandatory to minimize seizure risk 4, 5
• Second dose should not be taken late in the day to minimize insomnia 3
• Onset of action: 2 weeks, with full efficacy at 4 weeks 4

For Smoking Cessation:

• Initiate 1-2 weeks prior to quit date 3
• Days 1-3: 150 mg orally once daily 3
• Day 4 through 7-12 weeks: 150 mg orally twice daily (if tolerated) 3
• Duration: 7-12 weeks initially; may extend to 6 months-1 year for continued cessation 3

Dose Adjustments:

Renal Impairment:

• Moderate to severe: Reduce total daily dose by one-half 3
• End-stage renal disease: Avoid use 3

Hepatic Impairment:

• Moderate to severe: Maximum 1 tablet daily (for combination products) 3
• Bupropion is extensively metabolized by the liver with half-life of approximately 21 hours 5

---

Absolute Contraindications

Critical Safety Exclusions:

1. Seizure disorders or conditions that lower seizure threshold:

   • Active epilepsy 3
   • History of stroke 3
   • Brain metastases 3
   • Anorexia or bulimia nervosa 3
   • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 3

2. MAO inhibitor use:

   • Concurrent use or within 14 days of MAOIs (increased risk of hypertensive reactions) 3

3. Closed-angle glaucoma 3

4. Concurrent tamoxifen use (for smoking cessation indication) 3

5. Uncontrolled hypertension (particularly for naltrexone-bupropion combination) 3

---

Monitoring Recommendations

Baseline Assessment:

• Screen for seizure risk factors - This is the most critical safety consideration given the 0.1% seizure incidence when properly dosed 6, 7
• Blood pressure measurement - Essential before initiating therapy 3
• Psychiatric history - Assess for suicidal ideation, particularly in patients <24 years old 3

Ongoing Monitoring:

Neuropsychiatric Surveillance:

• Monitor for development or worsening of depression, suicidal ideation/behavior, hostility, or agitation - This carries a black box warning, though the EAGLES trial (n=8,058) found no significant increase in neuropsychiatric adverse events compared to placebo 3
• Particularly vigilant monitoring required in patients <24 years old 3

Cardiovascular Monitoring:

• Vital signs at each visit - Blood pressure and heart rate 3
• No significant changes in mean heart rate or blood pressure reported in clinical trials 6
• Major cardiovascular events not significantly increased (RR 0.57,95% CI 0.31-1.04) 3

Efficacy Assessment:

• For weight management: Discontinue if <5% total body weight loss after 12 weeks at maintenance dose 3
• For depression: Assess response at 2-4 weeks; consider switching if inadequate response 3, 4

---

Common Adverse Effects & Management

Most Frequent Side Effects:

Tolerability Profile (in order of frequency):

1. Insomnia (most common) - Dose second administration earlier in day; avoid late-day dosing 3, 6
2. Dry mouth - Generally transient, resolves without intervention 4, 6, 7
3. Headache 4, 6
4. Nausea 4, 6
5. Anxiety/agitation - May represent nicotine withdrawal when used for smoking cessation 6

Advantages Over Other Antidepressants:

• Minimal sexual dysfunction compared to SSRIs 3, 2
• Less weight gain than tricyclic antidepressants 2
• Less somnolence than SSRIs and TCAs 2
• 10-100 times less likely to cause cardiac conduction problems than tricyclics 7

Serious Adverse Events:

Seizures:

• Incidence: 0.1% at recommended doses (≤300 mg/day for SR formulation) when patients properly screened 6, 7
• Risk increases with doses >450 mg/day for IR or >400 mg/day for SR 4, 5
• Bupropion lowers seizure threshold via dopaminergic mechanisms 3

Hypersensitivity Reactions:

• Incidence: 0.1% in controlled trials 6

Cardiovascular:

• Serious cardiovascular adverse events comparable to placebo 3
• Discontinuation rate due to adverse events: 6-12% in clinical trials 6

---

Drug Interactions

Critical Interactions:

CYP2B6 Substrates:

• Bupropion is extensively metabolized by CYP2B6 to hydroxybupropion (primary active metabolite) 5, 8
• CYP2B6 polymorphisms significantly influence bupropion disposition but not clinical outcomes 8

CYP2D6 Inhibition:

• Bupropion inhibits CYP2D6, potentially reducing clearance of drugs metabolized by this enzyme 5

Seizure Threshold-Lowering Agents:

• Use cautiously with other medications that lower seizure threshold 1, 5

Opioids (for naltrexone-bupropion combination):

• Discontinue before procedures requiring opioid analgesia (e.g., endoscopy with fentanyl) 3
• May precipitate withdrawal in opioid-dependent patients 3

---

Special Clinical Considerations

Patient Selection Priorities:

Ideal Candidates:

• Depressed patients with comorbid smoking - Addresses both conditions simultaneously 3
• Patients concerned about sexual dysfunction - Bupropion has minimal impact on sexual function 3, 2
• Patients with comorbid depression and need for weight management (naltrexone-bupropion) 3
• Patients with low energy/motivation - Dopaminergic effects may provide activating benefits 4

Poor Candidates:

• Patients with any seizure risk factors 3
• Patients requiring chronic opioid therapy (for combination products) 3
• Patients with severe anxiety (may worsen initially, though data are mixed) 9
• Patients with uncontrolled hypertension 3

Pregnancy & Lactation:

• FDA pregnancy category C 1
• Risk-benefit assessment required; no major teratogenic signals but limited data 1

Geriatric Use:

• No specific dose adjustment required, but start at lower end of dosing range 1
• Monitor closely for adverse effects given potential for multiple comorbidities 1

---

Discontinuation

Tapering is recommended to minimize withdrawal symptoms, though specific taper schedules are not mandated 1

---

Clinical Pearls

1. Bupropion is the only antidepressant with no appreciable serotonergic activity - making it uniquely suited for patients who cannot tolerate SSRIs 4

2. Three active metabolites contribute to therapeutic effect: hydroxybupropion (50% as active), threohydrobupropion and erythrohydrobupropion (20% as active) 4, 5

3. Combination with NRT is safe and effective for smoking cessation, despite theoretical concerns about nicotine toxicity 3

4. Neuropsychiatric safety concerns are overstated - The EAGLES trial definitively showed no increased risk compared to placebo in patients with or without psychiatric disorders 3

5. For treatment-resistant depression: Bupropion augmentation of SSRIs shows similar efficacy to other augmentation strategies 3